ADC Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ADC Therapeutics SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11161
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ADC Therapeutics SA (ADCT) is a pharmaceutical company that develops a pipeline of proprietary antibody drug conjugates for the treatment of both solid and hematological cancers. The company offers combining monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine -based warheads to selectively kill cancer cells. It conducts research on next-generation cancer biologic therapies. ADCT targets a wide range of cancers such as breast lung, prostate, renal, blood cancer, and others. The company has exclusive technology license partnership with Spirogen for the development of PBD-based Antibody-Drug-Conjugates. It also has corporate partnerships with MedImmune, Cancer Research Technology, Genmab, and others. ADCT is headquartered in Lausanne, Switzerland.

ADC Therapeutics SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
ADC Therapeutics To Raise US$50 Million In Venture Financing 12
Private Equity 14
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 14
Partnerships 15
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 15
Genmab Enters into Co-Development Agreement with ADC Therapeutics 16
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 17
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 18
Licensing Agreements 20
ADC Therapeutics Enters into Licensing Agreement with Synaffix 20
ADC Therapeutics Exercises Option for Licensing Agreement with LivTech 21
ADC Therapeutics Enters into Licensing Agreement with Chiome Bioscience 22
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 23
Synaffix Enters into Licensing Agreement with ADC Therapeutics 24
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 25
ADC Therapeutics Enters Into Licensing Agreement With BZL Biologics 27
ADC Therapeutics Enters Into Licensing Agreement With VivaMab For VM101 28
Equity Offering 29
ADC Therapeutics May Raise Funds through IPO of Shares 29
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 30
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 31
ADC Therapeutics SA – Key Competitors 32
ADC Therapeutics SA – Key Employees 33
ADC Therapeutics SA – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Product Approvals 35
Jun 09, 2017: ADC Therapeutics Receives Orphan Drug Designation for ADCT-402 for the Treatment of Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma 35
Clinical Trials 36
Apr 13, 2018: Promising pre-clinical data supporting BerGenBios pipeline to be published and presented at upcoming leading conferences 36
Apr 11, 2018: ADC Therapeutics to Present New Investigational Antibody-Drug Conjugate ADCT-601 at the American Association for Cancer Research (AACR) Annual Meeting 37
Apr 11, 2018: ADC Therapeutics to Present on its Lymphoid Malignancies Drug Candidate DCT-301 at the American Association for Cancer Research (AACR) Annual Meeting 38
Dec 11, 2017: ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301 39
Dec 11, 2017: ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402 41
Nov 15, 2017: ADC Therapeutics to Present New Clinical Data for ADCT-402 at American Society of Hematology 2017 Annual Meeting 43
Nov 15, 2017: ADC Therapeutics to Present New Clinical Data on ADCT-301 at the American Society of Hematology 2017 Annual Meeting 44
Jun 16, 2017: ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma 45
Jun 16, 2017: ADC Therapeutics Presents Interim Data from the First Clinical Study of its Novel Antibody-Drug Conjugate ADCT-301 at the 14-ICML 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Key Facts 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Deals By Therapy Area, 2012 to YTD 2018 9
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADC Therapeutics To Raise US$50 Million In Venture Financing 12
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 14
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 15
Genmab Enters into Co-Development Agreement with ADC Therapeutics 16
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 17
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 18
ADC Therapeutics Enters into Licensing Agreement with Synaffix 20
ADC Therapeutics Exercises Option for Licensing Agreement with LivTech 21
ADC Therapeutics Enters into Licensing Agreement with Chiome Bioscience 22
ADC Therapeutics Enters into Licensing Agreement with BerGenBio 23
Synaffix Enters into Licensing Agreement with ADC Therapeutics 24
ADC Therapeutics Enters Into Licensing Agreement With Five Prime Therapeutics 25
ADC Therapeutics Enters Into Licensing Agreement With BZL Biologics 27
ADC Therapeutics Enters Into Licensing Agreement With VivaMab For VM101 28
ADC Therapeutics May Raise Funds through IPO of Shares 29
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 30
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 31
ADC Therapeutics SA, Key Competitors 32
ADC Therapeutics SA, Key Employees 33
ADC Therapeutics SA, Other Locations 34

List of Figures
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADC Therapeutics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ADC Therapeutics SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aban Offshore Ltd (ABAN):石油・ガス:M&Aディール及び事業提携情報
    Summary Aban Offshore Limited (AOL) is an offshore drilling company. It offers offshore drilling and oilfield services to the companies which carry out the exploration, development and production of oil and gas both in domestic and international markets. The company’s service portfolio includes dril …
  • Anavex Life Sciences Corp (AVXL)-製薬・医療分野:企業M&A・提携分析
    Summary Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, other central nervous system (CNS) diseases, pain and various types of cancer. The c …
  • Allergan plc:企業のM&A・事業提携・投資動向
    Allergan plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allergan plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Zebra Technologies Corporation:企業の戦略・SWOT・財務情報
    Zebra Technologies Corporation - Strategy, SWOT and Corporate Finance Report Summary Zebra Technologies Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • PetroRio SA (PRIO3):企業の財務・戦略的SWOT分析
    Summary PetroRio SA (PetroRio), formerly HRT Participacoes em Petroleo SA, a subsidiary of HRT Oil & Gas Ltd, is oil and gas company. It offers investment and recovering of oil production assets. The company provides development of solid growth platforms aiming to generate value to its shareholders …
  • ChemRar High-Tech Center:製薬・医療:M&Aディール及び事業提携情報
    Summary ChemRar High-Tech Center (CHTC) is a developer of drugs for life-threatening diseases. The company offers drugs for the treatment of cancer, central nervous system, infectious, metabolic and cardiovascular diseases. It also offers pre-clinical and clinical research of new molecules including …
  • VTB Bank:戦略・SWOT・企業財務分析
    VTB Bank - Strategy, SWOT and Corporate Finance Report Summary VTB Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • China Shenhua Energy Co Ltd:企業の戦略・SWOT・財務情報
    China Shenhua Energy Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China Shenhua Energy Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Santhera Pharmaceuticals Holding AG (SANN):製薬・医療:M&Aディール及び事業提携情報
    Summary Santhera Pharmaceuticals Holding AG (Santhera) develops and commercializes novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. It specifically focuses in the area of neuromuscular and neuro-ophthalmological conditions. The company’s lead produc …
  • Infratil Ltd (IFT):企業の財務・戦略的SWOT分析
    Infratil Ltd (IFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • The Swatch Group Ltd (UHR):企業の財務・戦略的SWOT分析
    The Swatch Group Ltd (UHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Daepyung Co., Ltd.:戦略・SWOT・企業財務分析
    Daepyung Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daepyung Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Monsanto Co (MON):企業の財務・戦略的SWOT分析
    Monsanto Co (MON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Caixa Economica Federal:企業の戦略・SWOT・財務情報
    Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report Summary Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Denison Mines Corp (DNN):企業の財務・戦略的SWOT分析
    Denison Mines Corp (DNN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • EyePoint Pharmaceuticals Inc (PSDV):医療機器:M&Aディール及び事業提携情報
    Summary EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert …
  • UNeMed Corp:医療機器:M&Aディール及び事業提携情報
    Summary Unemed Corp (Unemed), a subsidiary of University of Nebraska Medical Center, is a healthcare service provider. The company offers services such as inventions, material transfer, confidentiality, intellectual property, startup formation and licensing process. Its technologies include therapeu …
  • LG Electronics, Inc.:企業の戦略・SWOT・財務情報
    LG Electronics, Inc. - Strategy, SWOT and Corporate Finance Report Summary LG Electronics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Comair Limited:企業の戦略・SWOT・財務情報
    Comair Limited - Strategy, SWOT and Corporate Finance Report Summary Comair Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Petroleum Company of Trinidad and Tobago Ltd:企業の戦略的SWOT分析
    Petroleum Company of Trinidad and Tobago Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆